ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 384 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
384 citing papers in PubMed, 7 syntheses or guidelines pooled it, 847 citations in OpenAlex.
- Diagnostic valuation of MMP family members as biomarkers for pancreatic cancer: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk.Scientific reports · 2024Pooled it
- Conservation of Epithelial-to-Mesenchymal Transition Process in Neural Crest Cells and Metastatic Cancer.Cells, tissues, organs · 2021Pooled it
- The Role of MMP8 in Cancer: A Systematic Review.International journal of molecular sciences · 2019Pooled it
- Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies.Medicine · 2018Pooled it
- Association between ADAM12 Single-Nucleotide Polymorphisms and Knee Osteoarthritis: A Meta-Analysis.BioMed research international · 2017Pooled it
- Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review.EBioMedicine · 2016Pooled it
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Review
- Article
- Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.Accounts of chemical research · 2026Article
- A DLEU2/E2F1 regulatory axis promotes migration and invasion phenotypes in cervical squamous cell carcinoma.Scientific reports · 2026Article
- Role of the NHE1 exchanger in the antitumor effects of copper(II) complexes and phenanthroline derivatives.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026Article
- Article
- The effect of lidocaine in breast cancer: a concise overview of preclinical and clinical evidence.Frontiers in pharmacology · 2026Review
- Emerin acts as a mechanosensor linking force transmission and disease.Frontiers in oncology · 2026Review
- Anticancer Effects of Sacha Inchi (International journal of molecular sciences · 2025Article
- Anti-Metastatic Effects ofInternational journal of molecular sciences · 2025Article
- MicroRNA-125b-5p Drives MMP-2 Expression via Activation of RAGE-38MAPK-p65/p50NF-κB Axis: A Novel Mechanism in Human Lung Cancer Cells.International journal of molecular sciences · 2025Article
324 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The matrix metalloproteinase (MMP) family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in a number of key normal and pathologic processes. The latter include tumor growth, progression, and metastasis as well as the dysregulated angiogenesis that is associated with these events. As a result, these proteases have come to represent important therapeutic and diagnostic targets for the treatment and detection of human cancers. In this review, we summarize the literature that establishes these enzymes as important clinical targets, discuss the complexity surrounding their choice as such, and chronicle the development strategies and outcomes of their clinical testing to date. The status of the MMP inhibitors currently in US Food and Drug Administration approved clinical trials is presented and reviewed. We also discuss the more recent and successful targeting of this enzyme family as diagnostic and prognostic predictors of human cancer, its status, and its stage. This analysis includes a wide variety of human cancers and a number of human sample types including tissue, plasma, serum, and urine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.